We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

MedXY Editorial Team•Dec 29, 2025•Diabetes & Endocrinology
diabetesimmunotherapyoncology

Highlights

Analysis of 13,966 patients across 158 National Cancer Institute (NCI) trials highlights that immune checkpoint inhibitor-induced diabetes (ICI-D) has an overall cumulative incidence of 0.52%.

The risk of ICI-D is significantly higher with combination immunotherapy (OR 2.68) compared to PD-1/PD-L1 monotherapy, whereas concurrent chemotherapy appears to reduce the risk (OR 0.38).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Advancing Sentinel Lymph Node Biopsy in Vulvar Cancer: Real-Time Near-Infrared Fluorescence Imaging Enhances Detection and SafetyA recent study demonstrates the feasibility and safety of hybrid indocyanine green and technetium-99m nanoparticle fluorescence imaging for sentinel lymph node biopsy in early-stage vulvar cancer, improving detection rates and oncologic outSep 25, 2026The Central Role of Guilt in Daily Diabetes-Specific Emotional Burdens: Insights from Intensive Longitudinal Network AnalysisThis study highlights how daily feelings of guilt are central drivers of negative emotional burdens in diabetes, influencing emotional well-being and risk of distress and depression.Sep 25, 2026Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell CarcinomaThis study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.Sep 22, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.
Sep 22, 2026
Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver CancerThis longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.Sep 21, 2026
From Alert to Action: Enhancing Diabetes Self-Management Referrals Through Electronic Health Record AlertsA cluster-randomized trial demonstrates that integrating best practice advisories (BPAs) and standing orders into electronic health records significantly improves referral rates to diabetes self-management education and support (DSMES) overSep 21, 2026